{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:40:47Z","timestamp":1771850447068,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The expression level of BCMA in bone marrow of 54 MM patients was detected in this study to explore the relationship between the BCMA expression and the classification, stage, and prognostic factors of MM. The BCMA expression level of the stable group and remission group was lower than that of the newly diagnosed group and relapse group (P=0.001). There was no significant difference in BCMA expression of MM patients in different types and stages (P&amp;gt;0.05), but it was found that for the newly diagnosed MM patients, the BCMA expression level of IgG patients was higher than that of IgA or light-chain patients (rank average 11.20 <jats:italic>vs<\/jats:italic> 5.44, P=0.014). There was no significant correlation between the BCMA expression and the age and serum creatinine of MM patients (P&amp;gt;0.05). And there was no significant difference in BCMA expression between patients with different levels of age and serum creatinine (P&amp;gt;0.05). But it was found that the BCMA expression level of the newly diagnosed MM patients was moderately positively correlated with their age (P=0.025, r=0.595). There was no significant correlation between the BCMA expression and serum \u03b22-microglobulin, serum lactate dehydrogenase, free kap\/lam ratio, and urine \u03b22-microglobulin (P&amp;gt;0.05). But we found that the BCMA expression of patients with high serum \u03b22-microglobulin was higher than that of patients with low serum \u03b22-microglobulin (rank average 28.89 <jats:italic>vs<\/jats:italic> 17.54, P=0.017). And the BCMA expression of patients with abnormal serum free kap\/lam ratio was higher than that of patients with normal ratio (rank average 28.49 <jats:italic>vs<\/jats:italic> 13.55, P=0.004). The BCMA expression was strongly positively correlated with 24-h urine protein, was moderately positively correlated with serum M protein and the percentage of plasma cells in bone marrow, was moderately negatively correlated with albumin and hemoglobin count, and was weakly positively correlated with serum corrected calcium (P&amp;lt;0.05). And it was found that the BCMA expression of positive serum immunofixation electrophoresis patients was higher than that of negative patients (rank average 29.94 <jats:italic>vs<\/jats:italic> 16.75, P=0.017). And we try to clarify the relationship between the bone marrow BCMA expression and the peripheral blood sBCMA expression. However, we have not found a clear correlation between them so far (P&amp;gt;0.05).<\/jats:p>","DOI":"10.3389\/fimmu.2021.724411","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T09:24:25Z","timestamp":1637227465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Study on the Relationship Between the Expression of B Cell Mature Antigen and the Classification, Stage, and Prognostic Factors of Multiple Myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Tiantian","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyue","family":"Bian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jincheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengchang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huasheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple Myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab Plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.624661","article-title":"Daratumumab for the Management of Newly Diagnosed and Relapsed\/Refractory Multiple Myeloma: Current and Emerging Treatments","volume":"10","author":"Offidani","year":"2020","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03323-6","article-title":"Elotuzumab, Pomalidomide, and Dexamethasone Is a Very Well Tolerated Regimen Associated With Durable Remission Even in Very Advanced Myeloma: A Retrospective Study From Two Academic Centers","volume":"147","author":"Hose","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313","article-title":"Continued Improvement in Survival in Multiple Myeloma: Changes in Early Mortality and Outcomes in Older Patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.23736\/S0031-0808.20.04121-X","article-title":"BCMA-Targeting Approaches for Treatment of Multiple Myeloma","volume":"63","author":"Chen","year":"2021","journal-title":"Panminerva Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple Myeloma Epidemiology and Survival: A Unique Malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1909469","article-title":"A New Decade: Novel Immunotherapies on the Horizon for Relapsed\/Refractory Multiple Myeloma","volume":"14","author":"Braunstein","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-03592-9","article-title":"Chimeric Antigen Receptor T Cell Targeting B Cell Maturation Antigen Immunotherapy Is Promising for Multiple Myeloma","volume":"98","author":"Ma","year":"2019","journal-title":"Ann Hematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy Bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.632937","article-title":"Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma","volume":"12","author":"Jasin\u00b4 ski","year":"2021","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3390\/cancers11122024","article-title":"Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma","volume":"11","author":"Hosen","year":"2019","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-Cell Maturation Antigen Is a Promising Target for Adoptive T-Cell Therapy of Multiple Myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective Targeting of Multiple BCMA-Expressing Hematological Malignancies by Anti-BCMA CAR T Cells","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/sci-2020-029","article-title":"Novel Progresses of Chimeric Antigen Receptor (CAR) T Cell Therapy in Multiple Myeloma","volume":"8","author":"Ding","year":"2021","journal-title":"Stem Cell Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2019.05.053","article-title":"Advance of Research on the Immunotherapy Targeting B Cell Maration Antigen for Multiple Myeloma\u2013Review","volume":"27","author":"Luan","year":"2019","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0373-2","article-title":"CARs in the Lead Against Multiple Myeloma","volume":"12","author":"Ormh\u00f8j","year":"2017","journal-title":"Curr Hematol Malignancy Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41375-019-0669-4","article-title":"Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma: Can We do Better","volume":"34","author":"D\u2019Agostino","year":"2020","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B Cell Maturation Antigen-Specific CAR T Cells Are Clinically Active in Multiple Myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells Genetically Modified to Express an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.4413.4413","article-title":"Serum Bcma May Interfere With Anti-Bcma-CAR-Transduced T Cells or Other Anti-Bcma Antibody-Based Immunotherapy in Multiple Myeloma","volume":"130","author":"Chen","year":"2017","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase Inhibition Increases Efficacy of BCMA-Specific Chimeric Antigen Receptor T Cells in Multiple Myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116898","article-title":"T Cells Expressing Anti B-Cell Maturation Antigen Chimeric Antigen Receptors for Plasma Cell Malignancies","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903","article-title":"T Cells Expressing an Anti\u2013B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Multiple Myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0578-1426.2017.11.021","article-title":"[The Guidelines for the Diagnosis and Management of Multiple Myeloma in China (2017 Revision)]","volume":"56","year":"2017","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn.112138-20200304-00179","article-title":"[The Guidelines for the Diagnosis and Management of Multiple Myeloma in China(2020 Revision)]","volume":"59","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/cells8121522","article-title":"Therapeutic Opportunities With Pharmacological Inhibition of CD38 With Isatuximab","volume":"8","author":"Martin","year":"2019","journal-title":"Cells"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-731885","article-title":"Targeting the PD-1\/PD-L1 Axis in Multiple Myeloma: A Dream or a Reality","volume":"129","author":"Rosenblatt","year":"2017","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3547-7","article-title":"Copanlisib, A Novel Phosphoinositide 3-Kinase Inhibitor, Combined With Carfilzomib Inhibits Multiple Myeloma Cell Proliferation","volume":"98","author":"Okabe","year":"2019","journal-title":"Ann Hematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, Bortezomib, and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide (OPTIMISMM): A Randomised, Open-Label, Phase 3 Trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 Patients With Newly Diagnosed Multiple Myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.13.10724","article-title":"Tumor Load in Patients With Multiple Myeloma: \u03b2 2 -Microglobulin Levels Versus Whole-Body MRI","volume":"203","author":"D\u2019Anastasi","year":"2014","journal-title":"Am J Roentgenol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/0004563213518758","article-title":"Serum-Free Light-Chain Assay: Clinical Utility and Limitations","volume":"51","author":"Bhole","year":"2014","journal-title":"Ann Clin Biochem"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.03.010","article-title":"Immunologic Approaches for the Treatment of Multiple Myeloma","volume":"55","author":"Rasche","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020336","article-title":"Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications","volume":"10","author":"IJ","year":"2021","journal-title":"Cells"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic Complexity of Multiple Myeloma and Its Clinical Implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.056176","article-title":"Report From the European Myeloma Network on Interphase FISH in Multiple Myeloma and Related Disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-03915-9","article-title":"Early Monoclonal Protein Decline Pattern Is an Independent Prognostic Factor in Patients With Multiple Myeloma","volume":"99","author":"Liu","year":"2020","journal-title":"Ann Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.724411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T09:24:30Z","timestamp":1637227470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.724411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2021.724411"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.724411","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"article-number":"724411"}}